480 related articles for article (PubMed ID: 23981744)
1. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
Yeo SI
Int J Rheum Dis; 2013 Jun; 16(3):254-7. PubMed ID: 23981744
[TBL] [Abstract][Full Text] [Related]
2. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
[TBL] [Abstract][Full Text] [Related]
3.
Ponzo MG; Miliszewski M; Kirchhof MG; Keown PA; Dutz JP
J Cutan Med Surg; 2019; 23(6):595-601. PubMed ID: 31378082
[TBL] [Abstract][Full Text] [Related]
4. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population.
Gonçalo M; Coutinho I; Teixeira V; Gameiro AR; Brites MM; Nunes R; Martinho A
Br J Dermatol; 2013 Sep; 169(3):660-5. PubMed ID: 23600531
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.
Yu KH; Yu CY; Fang YF
Int J Rheum Dis; 2017 Sep; 20(9):1057-1071. PubMed ID: 28857441
[TBL] [Abstract][Full Text] [Related]
6. Human leukocyte antigens and drug hypersensitivity.
Chung WH; Hung SI; Chen YT
Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):317-23. PubMed ID: 17620823
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.
Hershfield MS; Callaghan JT; Tassaneeyakul W; Mushiroda T; Thorn CF; Klein TE; Lee MT
Clin Pharmacol Ther; 2013 Feb; 93(2):153-8. PubMed ID: 23232549
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.
Chong HY; Lim YH; Prawjaeng J; Tassaneeyakul W; Mohamed Z; Chaiyakunapruk N
Pharmacogenet Genomics; 2018 Feb; 28(2):56-67. PubMed ID: 29176400
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States.
Jutkowitz E; Dubreuil M; Lu N; Kuntz KM; Choi HK
Semin Arthritis Rheum; 2017 Apr; 46(5):594-600. PubMed ID: 27916277
[TBL] [Abstract][Full Text] [Related]
10. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity?
Dainichi T; Uchi H; Moroi Y; Furue M
Dermatology; 2007; 215(1):86-8. PubMed ID: 17587850
[No Abstract] [Full Text] [Related]
11. HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case-control clinical study.
Cheng L; Xiong Y; Qin CZ; Zhang W; Chen XP; Li J; Zhou HH
Br J Dermatol; 2015 Aug; 173(2):555-8. PubMed ID: 26104483
[No Abstract] [Full Text] [Related]
12. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.
Hung SI; Chung WH; Liou LB; Chu CC; Lin M; Huang HP; Lin YL; Lan JL; Yang LC; Hong HS; Chen MJ; Lai PC; Wu MS; Chu CY; Wang KH; Chen CH; Fann CS; Wu JY; Chen YT
Proc Natl Acad Sci U S A; 2005 Mar; 102(11):4134-9. PubMed ID: 15743917
[TBL] [Abstract][Full Text] [Related]
13. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Analysis of Triggers and Implications for Improving Prevention.
Miliszewski MA; Kirchhof MG; Sikora S; Papp A; Dutz JP
Am J Med; 2016 Nov; 129(11):1221-1225. PubMed ID: 27086495
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population.
Saokaew S; Tassaneeyakul W; Maenthaisong R; Chaiyakunapruk N
PLoS One; 2014; 9(4):e94294. PubMed ID: 24732692
[TBL] [Abstract][Full Text] [Related]
15. Allopurinol pharmacogenetics: assessment of potential clinical usefulness.
Zineh I; Mummaneni P; Lyndly J; Amur S; La Grenade LA; Chang SH; Rogers H; Pacanowski MA
Pharmacogenomics; 2011 Dec; 12(12):1741-9. PubMed ID: 22118056
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions.
Ke CH; Chung WH; Wen YH; Huang YB; Chuang HY; Tain YL; Wang YL; Wu CC; Hsu CN
J Rheumatol; 2017 Jun; 44(6):835-843. PubMed ID: 28365572
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.
Dong D; Tan-Koi WC; Teng GG; Finkelstein E; Sung C
Pharmacogenomics; 2015 Nov; 16(16):1781-93. PubMed ID: 26554739
[TBL] [Abstract][Full Text] [Related]
18. Human leukocyte antigen-B*58:01 allele in a familial case of Stevens-Johnson syndrome induced by allopurinol.
Caldarola G; Sollena P; Peris K; De Simone C
J Dermatol; 2015 Jul; 42(7):753-4. PubMed ID: 25899558
[No Abstract] [Full Text] [Related]
19. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Cristallo AF; Schroeder J; Citterio A; Santori G; Ferrioli GM; Rossi U; Bertani G; Cassano S; Gottardi P; Ceschini N; Barocci F; Ribizzi G; Cutrupi V; Cairoli R; Rapisarda V; Pastorello EA; Barocci S
Int J Immunogenet; 2011 Aug; 38(4):303-9. PubMed ID: 21545408
[TBL] [Abstract][Full Text] [Related]
20. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.
Lonjou C; Borot N; Sekula P; Ledger N; Thomas L; Halevy S; Naldi L; Bouwes-Bavinck JN; Sidoroff A; de Toma C; Schumacher M; Roujeau JC; Hovnanian A; Mockenhaupt M;
Pharmacogenet Genomics; 2008 Feb; 18(2):99-107. PubMed ID: 18192896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]